一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion.
Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤细胞内在信号通路可显著影响肿瘤免疫微环境,通过将免疫细胞群体排除在肿瘤之外,促进肿瘤进展和对免疫治疗的耐药。已有若干肿瘤细胞内在通路被报道可调节髓系细胞和T细胞浸润,形成“冷”肿瘤。
然而,临床证据提示,将细胞毒性T细胞排除在肿瘤核心之外同样介导免疫逃逸。在本研究中,我们发现非小细胞肺癌中肿瘤细胞内在SOX2信号诱导细胞毒性T细胞从肿瘤核心排除,并促进对检查点阻断治疗的耐药。在机制上,肿瘤细胞内在SOX2表达上调肿瘤细胞中的CCL2,导致调节性T细胞(Treg)募集增加。CD8+ T细胞排除依赖于Treg对肿瘤血管的抑制。通过糖皮质激素诱导的TNF受体相关蛋白清除肿瘤浸润性Treg可恢复CD8+ T细胞浸润,并与检查点阻断治疗联合时减少肿瘤生长。这些结果表明,肺癌中肿瘤细胞内在SOX2表达是免疫治疗耐药的一种机制,并为未来研究提供证据支持,以探讨具有SOX2依赖性CD8+ T细胞排除的非小细胞肺癌患者是否能从清除糖皮质激素诱导的TNFR相关蛋白阳性Treg中获益。
Tumor cell-intrinsic signaling pathways can drastically affect the tumor immune microenvironment, promoting tumor progression and resistance to immunotherapy by excluding immune cell populations from the tumor. Several tumor cell-intrinsic pathways have been reported to modulate myeloid-cell and T-cell infiltration, creating "cold" tumors.
However, clinical evidence suggests that excluding cytotoxic T cells from the tumor core also mediates immune evasion. In this study, we find that tumor cell-intrinsic SOX2 signaling in non-small cell lung cancer induces the exclusion of cytotoxic T cells from the tumor core and promotes resistance to checkpoint blockade therapy.
Mechanistically, tumor cell-intrinsic SOX2 expression upregulates CCL2 in tumor cells, resulting in increased recruitment of regulatory T cells (Treg). CD8+ T-cell exclusion depended on Treg-mediated suppression of tumor vasculature. Depleting tumor-infiltrating Tregs via glucocorticoid-induced TNF receptor-related protein restored CD8+ T-cell infiltration and, when combined with checkpoint blockade therapy, reduced tumor growth.
These results show that tumor cell-intrinsic SOX2 expression in lung cancer serves as a mechanism of immunotherapy resistance and provide evidence to support future studies investigating whether patients with non-small cell lung cancer with SOX2-dependent CD8+ T-cell exclusion would benefit from the depletion of glucocorticoid-induced TNFR-related protein-positive Tregs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。